<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02892812</url>
  </required_header>
  <id_info>
    <org_study_id>LG-VECL001</org_study_id>
    <nct_id>NCT02892812</nct_id>
  </id_info>
  <brief_title>A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults</brief_title>
  <official_title>A Single-blind, Single-center, Randomized, Active-controlled, Parallel Group, Phase I Study to Evaluate the Safety and Immunogenicity of Intramuscular Single Injection With LBVE013 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), LBVE014 (Pneumococcal 14-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) or Prevnar13 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of LBVE013
      (Pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) or LBVE014
      (Pneumococcal 14-valent conjugate vaccine [diphtheria CRM197 protein]) in healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Solicited adverse events</measure>
    <time_frame>Baseline(pre-vaccination) up to 7 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unsolicited adverse events</measure>
    <time_frame>Baseline(pre-vaccination) up to 4 weeks after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immediate reactions after vaccination</measure>
    <time_frame>Baseline(pre-vaccination) up to 30 minutes after vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 4 weeks After Vaccination</measure>
    <time_frame>4 weeks after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving 4-fold rise in Pneumococcal Opsonophagocytic Activity (OPA) titer at 4 weeks after vaccination</measure>
    <time_frame>4 weeks after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serotype-Specific Pneumococcal IgG antibody Geometric Mean Concentrations (GMCs) 4 weeks After Vaccination</measure>
    <time_frame>4 weeks after vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>LBVE013</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13-valent pneumococcal conjugate vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LBVE014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14-valent pneumococcal conjugate vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevnar13</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>13-valent pneumococcal conjugate vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal conjugate vaccine</intervention_name>
    <arm_group_label>LBVE013</arm_group_label>
    <arm_group_label>LBVE014</arm_group_label>
    <arm_group_label>Prevnar13</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult older than 19 years old and younger than 50 years old

          -  A subject who was informed of the purpose, method, and efficacy of the clinical study
             and signed the written informed consent form

        Exclusion Criteria:

          -  A subject who participated in other clinical studies within 3 months before screening

          -  A subject who was vaccinated with other vaccines within 4 weeks before screening, or
             who is expected to receive other vaccination during the clinical study period

          -  A subject with medical history of hypersensitive reactions (e.g. anaphylaxis) to the
             test drug or its ingredients

          -  A subject who received immunoglobulin or blood-derived materials within 3 months
             before screening

          -  A subject with immunologic function disorders including congenital or acquired
             immunodeficiency disorders

          -  A subject who is receiving immunosuppressive therapy or drugs that can affect
             immunological reaction

          -  A subject with pyrexia of over 38 Celsius degrees on the day of the vaccination with
             the investigational products

          -  A subject with medical history of Invasive Pneumococcal Disease (IPD) or pneumonia
             caused by Streptococcus pneumoniae

          -  A subject who was vaccinated with any pneumococcal vaccine before screening

          -  A subject who received the vaccine containing diphtheria toxoid within 6 months before
             screening (e.g. adult Td vaccine)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myoung-don Oh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2016</study_first_submitted>
  <study_first_submitted_qc>September 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>June 23, 2017</last_update_submitted>
  <last_update_submitted_qc>June 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

